Lunit Achieves Milestone at ECR 2025: 13 Oral Presentations Among 15 AI Studies, Demonstrating Unmatched Clinical Impact
Lunit to present 15 studies, with an unprecedented 13 accepted as oral presentations, marking a significant milestone in AI-powered radiology research Key studies demonstrate AI's capability to replace one radiologist in double reading, detect subclinical breast cancer years in advance, and maintain robust performance despite image quality challenges SEOUL, South...
Metabolon Unveils New Multiomics Biomarker Discovery Functionality via its Industry-leading Integrated Bioinformatics Platform
Metabolon's expertise extends beyond metabolomics to include data insights and software solutions for multiomics research MORRISVILLE, N.C., Feb. 27, 2025 /PRNewswire/ -- Metabolon, Inc., the global leader in providing metabolomics solutions advancing a wide variety of life science research, diagnostic, therapeutic development, and precision medicine applications, announces new multiomics biomarker discovery...
Nezha Craze Sweeps the City Wai Yuen Tong Proudly Sponsors Broadcast of “Nezha: The Demon Child Comes into the World” on Jade Channel
HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Hong Kong's traditional Chinese medicine pioneer Wai Yuen Tong (0897.HK) announced its proud sponsorship of the TVB Jade Channel's broadcast of the film " Nezha: The Demon Child Comes into the World " (Nezha 1) on February 28 at 8 PM. This film will provide viewers with an opportunity to revisit the classic...
So-Young Receives Approval to Transfer to Nasdaq Capital Market and Extension of Minimum Bid Price Compliance Period
BEIJING, Feb. 27, 2025 /PRNewswire/ -- So-Young International Inc. (NASDAQ: SY) ("So-Young" or the "Company"), the largest and most vibrant social community in China for consumers, professionals and service providers in the medical aesthetics industry, today announced that on February 25, 2025, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to...
Akeso Announces First ADC Drug Clinical Trial, Marking a New Era for “IO 2.0 + ADC” Strategy
HONG KONG, Feb. 27, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) announced the first patient has been enrolled in the Phase I clinical trial of AK138 D1 for the treatment of advanced malignancies in Australia. AK138D1, a self-developed and differentiated HER3-targeting ADC (antibody-drug conjugate), is Akeso's first ADC drug to enter clinical studies. Akeso is dedicated to transforming the...
WuXi Biologics Again Passed GMP Inspection by Japan PMDA
WUXI, China, Feb. 27, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for its drug substance facilities (MFG2 and MFG5), in Wuxi city. This onsite inspection covered the facilities' quality processes...
Clarivate Report Explores Opportunities for Innovation and Market Expansion in Latin America
New insights from Clarivate examine strategic partnerships, API production, and innovation in the region LONDON, Feb. 27, 2025 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) a leading global provider of transformative intelligence, has released a new white paper, How is Latin America Growing?, shedding light on the pharmaceutical industry's evolution in the region. The...
Alpro Foundation & Universiti Teknologi MARA: Addressing Malaysia’s Pharmaceutical Waste
KUALA LUMPUR, Malaysia, Feb. 27, 2025 /PRNewswire/ -- Malaysia is facing a growing environmental and public health threat due to improper disposal of pharmaceutical waste. Research indicates that 67% of Malaysians discard expired medications incorrectly—either by flushing them down the toilet or tossing them in regular trash—leading to contamination of the country's vital water sources. With 99% of Malaysia's...
Revolutionizing All-on-X: Medit’s Game-Changing Workflow Will Launch Soon
SEOUL, South Korea and NEWPORT BEACH, Calif., Feb. 27, 2025 /PRNewswire/ -- Medit (www.medit.com), a global leader in digital dentistry, is set to revolutionize the digital All-on-X workflow, making it more accessible, efficient, and intuitive for Medit scanner users. Medit SmartX Starting in March, Medit will introduce...
First Patient Dosed in a Phase III Clinical Study of Anti-HER2 Biparatopic ADC JSKN003 for the Treatment of HER2-positive Breast Cancer
SUZHOU, China, Feb. 27, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that the first patient has been successfully dosed in the Phase III clinical study (Study ID: JSKN003-301) of anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003. The study aims to compare the efficacy and safety of JSKN003...
